Tollys
  • About Us
    • Company
    • Board of Directors
    • Management
    • Scientific Advisory Board
  • Science
    • Immuno-oncology
    • TLR3 Science
    • Publications
  • Product
    • TL-532
    • Intellectual property
  • Pipeline
    • Bladder Cancer
    • TLR3+ Cancers
  • News
  • Careers
  • Contact
Select Page

Tollys closes pre-Series A
financing of €2.3 million

Logo Tollys

Funds will further development of a new cancer immunotherapy:  synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors

Read the article (EN)

-PDF : Tollys closes pre-series A

Lire l'article (FR)

– PDF : Tollys lève 2,3 millions d’euros lors d’une série A

Return


Tollys

A new dimension in immuno-oncology



Office

41 quai Fulchiron
69005 Lyon, FRANCE



Contact us

contact@tollys.fr 

Design by Small Stories ©2019